Urology Times staff

Eric Jonasch, MD, offers his advice for physicians treating patients with renal cell carcinoma.

Ali Raza Khaki, MD, discusses managing toxicities to ensure patients can continue to receive treatment with the antibody-drug conjugate enfortumab vedotin.

“We cannot give if our cup is empty,” says Diana Londoño, MD.

Sarah Elizabeth Yentz, MD, discusses what sequencing research and novel treatment development is needed to advance the metastatic renal cell carcinoma paradigm.

“The geographical discrepancies, the social discrepancies, and the impact of these discrepancies in the possibility for the patient to access any type of cure or surgical intervention is critical,” says Andrea Necchi, MD.

“I really foresee this becoming a very critical society in this area for many, many years to come,” says Philippe E. Spiess, MD, MS, FRCSC, FACS.

In the study, adding maintenance avelumab to best supportive care (BSC) led to a 31% reduction in the risk of death versus BSC alone in patients with unresectable locally advanced or metastatic urothelial cancer.

In this installment of our 50th Anniversary Innovation Celebration, Amy Pearlman, MD, interviews Mohit Khera, MD, MBA, MPH, on how advancements in testosterone therapy have changed treatment modalities across urology, providing patients with more efficacious, individualized care.

“I thought identity theft was simple. You fix this 1 little thing. Today, what physicians and health care professionals need to be on the lookout for is [that] it's much different,” says Mark A. Moyad, MD, MPH, on the latest Speaking of Urology podcast episode.

"This field has exploded!" says Mohit Khera, MD, MBA, MPH.

“It doesn't need to be surgery or radiation. Setting that stage, really focusing on those conversations, using the appropriate tools that we've grasped from behavioral psychologists that are being used by negotiation specialists, are critical in medicine,” says Behfar Ehdaie, MD, MPH.

The report provides information on the G84E mutation in the HOXB13 gene, which is linked to a significantly increased risk of developing prostate cancer.

“Our case discussion for January 18 is going to be focused on a patient who initially has biochemically recurrent prostate cancer [and] progresses to metastatic disease,” says Veda N. Giri, MD.

“We need to understand what the treatment [means] to them as individuals, and how they perceive the benefit of the treatment,” says Cornelia Haag, Molkenteller, MD, PhD.

Phillip Palmbos, MD, PhD, highlights four key questions that need to be answered in the first-line and neoadjuvant bladder cancer settings.

CheckMate-274 supported the FDA approval of nivolumab for the adjuvant treatment of patients with urothelial carcinoma.

“This analysis of this publication confirms the link between efficacy and the patient perception, and that the results are actually meaningful to the patients as well,” says Cornelia Haag-Molkenteller, MD. PhD.

“I think in specialized cases, especially for patients [who] need focal therapy or want focal therapy, or [for whom] you're really trying to minimize any nerve damage or urethral damage…these are excellent therapies,” says Jennifer Linehan, MD.

William J. Catalona, MD, explains how prostate-specific antigen (PSA) testing revolutionized screening and treatment of prostate cancer.

Phillip Palmbos, MD, PhD, explains the latest research findings on the role of chemoimmunotherapy in patients with bladder cancer.

"The fact that it was a simple blood test, it was absolutely objective, and it was…non-invasive…made it very attractive," says William J. Catalona, MD.

It's the hidden gem in medicine,” says Efe Chantal Ghanney Simons, MD.

“You can be 2 to 3 mm from another organ and still safely treat the tissue that you want to,” says Jennifer Linehan, MD.

Investigators evaluated data from the Continuous National Health and Nutrition Examination Survey.

“Going into this study, we thought that potentially patients who had a stent placed with the string left in place were at higher risk of having a complication…But we found that they weren't at higher risk of a complication,” says Amy E. Krambeck, MD.

In a recent interview, Channa Amarasekera, MD, discussed some of the challenges that sexual minorities face along with ways that clinicians can be more supportive toward this population of patients.

In a cohort of nearly 30,000 patients, more than half had cystoscopy-based stent removal within 6 months post ureteroscopy, investigators reported.

Eric Jonasch, MD, shares insight on the most pivotal developments in renal cell carcinoma over the past few years.

"Many people do not examine patients who come in with urinary tract infections or overactive bladder symptoms, and it’s a mistake,” says Rachel S. Rubin, MD.

“We find that consuming more healthy, plant-based foods is associated with a lower risk of aggressive and lethal prostate cancer, and has many other health benefits, too,” says Stacy Loeb, MD, PhD, MSc.